Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bellerophon Therapeutics, Inc.BLPH · Entity 108982 | Director | June 21, 2018 | June 25, 2018 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director · CHIEF EXECUTIVE OFFICER | November 21, 2025 | November 25, 2025 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bellerophon Therapeutics, Inc.
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 182,604 |
Reported balance
After 2018-06-21 transaction · row 1
1 source rowRow 1 · 2018-06-21 · Grant · Acquired 11,987 · Balance 182,604 |
DBV Technologies S.A.
Report date November 21, 2025 · Filed November 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2035-11-21 | Direct | 964,000 |
Reported balance
After 2025-11-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-21 · Grant · Acquired 964,000 · Balance 964,000 F1: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025. F2: The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025.
F2: The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,861 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001502785-26-000001 · primarydocument.xml · derivative · entry 2 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001502785-26-000001 · primarydocument.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 00:05 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 964,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001502785-25-000004 · form4-11242025_071101.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,000 Underlying: Ordinary Shares · 964,000 shares Expires 2035-11-21 F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025. F2 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004353 · primarydocument.xml · derivative · entry 2 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004353 · primarydocument.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 813,200 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-24-028393 · form4-12052024_041202.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 813,200 Underlying: Ordinary Shares · 813,200 shares Expires 2034-12-04 F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0511 to EURO 1.00 as of December 4, 2024. F2 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on December 4, 2025, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:40 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004650 · primarydocument.xml · derivative · entry 2 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:40 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004650 · primarydocument.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 20:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseOrdinary Shares | 17,094 | $0.83 | $14,188.02 |
DisclosureSEC source: 0001415889-24-007503 · form4-03112024_040312.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,094 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share. F2 · price: Represent the ADS price. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8123 to $0.8612 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 12:04 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 806,672 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-23-056409 · doc4.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806,672 Underlying: Ordinary Shares · 806,672 shares Expires 2033-11-20 F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0928 to EURO 1.00 as of November 20, 2023. F2 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:13 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004894 · primarydocument.xml · derivative · entry 2 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:13 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004894 · primarydocument.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| November 21, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 764,386 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-23-045642 · doc4.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,386 Underlying: Ordinary Shares · 764,386 shares Expires 2032-11-21 F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 15,324 | $0.00 Strike: $22.84 | $0.00 |
DisclosureSEC source: 0001562180-22-004881 · primarydocument.xml · derivative · entry 2 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004881 · primarydocument.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 274,000 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001209191-21-066789 · doc4.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,000 Underlying: Ordinary Shares · 274,000 shares Expires 2031-11-22 F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.underlying: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001562180-21-004131 · primarydocument.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:37 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001562180-20-004071 · primarydocument.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $43.02 | $0.00 |
DisclosureSEC source: 0001562180-19-003297 · primarydocument.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:33 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 11,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-18-000100 · wf-form4_152995877123610.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,604 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:53 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 38,216 | $2.27 Strike: $2.27 | $86,750.32 |
DisclosureSEC source: 0001600132-18-000072 · wf-form4_152840478940399.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,216 Underlying: Common Stock · 38,216 shares Expires 2028-06-04 Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:35 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-002719 · primarydocument.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 25, 2018. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 20:59 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001600132-17-000102 · wf-form4_150645953894625.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-21 F1 · derivative.exercise_date: This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 22:43 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 25,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-17-000065 · wf-form4_149886259042818.xml · nonDerivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,617 Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:02 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0000899243-17-014577 · doc4.xml · derivative · entry 1 Tasse Daniel · CIK 0001502785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 24, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.